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BACKGROUND: The prognostic value of tumor-infiltrating lymphocytes (TILs) in head and neck squamous cell
carcinoma (HNSCC) remains controversial. Additionally, there is no standardized approach or cutoff value for
evaluating TIL levels. The aim of this study was to establish a feasible method and criterion to assess TIL levels for
future clinical practice and research use and to explore the relationship between TIL levels and prognosis.
PATIENTS AND METHODS: This retrospective cohort study reviewed the records and pathological sections of 202
patients with HNSCC who were surgically treated at Beijing Stomatological Hospital, Capital Medical University,
from January 1998 to January 2011. The predictor variable was the TIL level. The main outcome assessment
parameters were disease-free survival (DFS) and disease-specific survival (DSS). RESULT: The T stage (P = .008),
smoking history (P = .042), alcohol history (P = .048), need for radiotherapy (P = .012) and microscopic
extracapsular spread (ECS) (P = .012) were associated with the TIL level. A cutoff value equal to 70% could be
taken as a threshold for TIL assessment, with a TIL level higher than 70% associated with a better prognosis (DFS
rate: 51.9%, P = .018; DSS rate: 59.3%, P = .049). The Cox regression model showed that the TIL level was an
independent prognostic factor for DFS (hazard ratio (HR): 0.786, 95% CI: 0.618-0.999, P = .049). CONCLUSION:
The TIL level is closely related to the prognosis of patients with HNSCC. A threshold value of 70% is appropriate
for TIL assessment, as patients with a TIL level higher than 70% show a better prognosis. Thus, the TIL level might
serve as an independent predictor for HNSCC recurrence.
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Approximately 635,000 new cases of head and neck cancer are
diagnosed each year worldwide, and over 90% of cases are squamous
cell carcinoma [1]. The treatments for head and neck squamous cell
carcinoma (HNSCC) are improving; however, despite surgery with or
without combined chemo-radiotherapy, the 5-year survival rate and
the recurrence rate remain poor [2]. Thus, novel variables that can
provide valuable information about prognosis are urgently needed for
HNSCC.
Tumor-infiltrating lymphocytes (TILs) have been used to predict
the prognosis of solid tumors for many years, as these cells serve as a
readout of the interaction between the immune system and cancer
cells [3]. There is emerging evidence to support the positive role of
TILs in HNSCC, but there remain some controversial issues, and no
standard process has been established for the evaluation of TILs. The
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cells and immune cells based on three phases: elimination,
equilibrium and escape. This relationship persists for the entire
duration of cancer progression [4]. Based on this theory, the
immune system can have a positive effect by eliminating tumor
cells, although the immune microenvironment may promote
malignant cells to become more aggressive and capable of escaping
immunological surveillance [5,6]. Although current studies have
presented arguments about the function of TILs, cumulative data
suggest that these mononuclear cells are associated with favorable
outcomes in squamous cell carcinoma and the response to
chemo-radiotherapy [7,8].
To explore the relationship between TILs and malignant
tumors, formal approaches to evaluate the level of TILs exist in
many fields, with the exception of HNSCC, and the TIL level has
been applied in the clinic and in research trials [9,10]. Some
pathologists even believe that TILs possess more predictive value than
conventional TNM staging.
In regards to HNSCC, the literature on TILs provides limited
evidence of their prognostic role, and many findings have been based
on small sample sizes [11]. Moreover, the different evaluation criteria
used make the results of different studies incomparable. Due to these
issues, an acceptable method to assess the level of TILs in HNSCC is
urgently needed. Based on the methods used to evaluate TILs in other
solid tumors (e.g., breast cancer, colorectal cancer, etc.) [9,10,12], in
this study, we sought to establish a standardized procedure for
measuring the TIL level and confirm the prognostic role of TIL levels
in HNSCC.
In this study, we used hematoxylin and eosin (H&E) staining to
observe and assess the infiltration of lymphocytes in the tumor
stromal area and then analyze the relationship between TIL level and
recurrence or survival rate. We focused on establishing a feasible
approach and criterion to evaluate TILs, with the hope that the
devised method can be used in common clinical practice and research
for pathological diagnosis and prognostic adjudication.
Methods
Patient Samples
This research was conducted in full accordance with ethical
principles, including the World Medical Association's Declaration of
Helsinki (2002 version) and with approval of the Institutional Review
Board of the Beijing Stomatological Hospital of Capital Medical
University. Patient inclusion criteria included the following: (1)
patients with a pathological diagnosis of squamous cell carcinoma; (2)
patients with a primary tumor without evidence of distant metastasis;
(3) patients who were treated primarily with surgery; (4) patients with
no previous treatment; (5) patients with complete clinicopathological
data and available tissue specimens; and (6) patients with a tumor
located in the tongue, lower gingiva, upper gingiva, buccal mucosa,
floor of the mouth, oropharynx, or hard palate. The exclusion criteria
included preoperative chemotherapy or radiotherapy, failure to
undergo surgery and the inability to obtain pathological slices. The
medical records of patients who met the inclusion criteria between
January 1998 and January 2011 for HNSCC at the Department of
Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomato-
logical Hospital, Capital Medical University were retrospectively
retrieved. All of the slides from the primary tumor sites for the
selected patients were obtained.Management
All patients underwent surgery for resection of the primary tumor.
The surgical procedure was selected by the surgeon according to the
tumor site and local practice. Standard surgery, including radical
tumor resection, neck dissection and the reconstruction of tissue
defects (as necessary), was performed. Local excision of the primary
site was performed with a minimum margin of 15 mm. Patients who
had UICC stages pT3 and 4, pN+, perineural invasion and/or
vascular emboli were recommended to receive radiation treatment,
whereas patients who presented with extracapsular spread and/or
positive margins were recommended to receive chemo-radiotherapy.
All tissue samples were obtained during the surgery and stored in
paraffin. Tissues embedded in paraffin were sectioned into 4 μm
sections and placed on a slide. After applying a standardized process
for H&E staining, the slides were observed under a microscope
(Olympus BX61) and scored using the approach described below.
Samples from patients with oropharyngeal squamous cell carcinoma
were also stained to assess the p16 status.
Approach and Threshold
For this study, we analyzed a significant amount of literature on
TILs, and the approach and criterion for evaluating the TIL level in
the stromal area were as follows (Figure 1):
a. Determine tumor area: We scanned the slide at low
magnification and determined the boundaries of the tumor
area. Only TILs inside the tumor boundaries were calculated.
b. Remove necrotic and degenerated tissue: After sketching the
boundaries, we removed necrotic and degenerated tissue inside
the tumor area.
c. Determine the type of tumor stromal area: The tumor stromal
area can be divided into three categories: cell-rich, moderate
and stroma-rich types. The cell-rich type is defined as more
than 70% of the tumor area composed of carcinoma cells or
tumor nest; when the stromal area is greater than 70%, it is
classified as the stroma-rich type. The moderate type is defined
as the intermediate situation.
d. Assess TILs by quantifying only mononuclear cells (e.g.,
lymphocytes and plasmocytes); neutrophils in necrotic areas,
dendritic cells and macrophages should be ruled out.
e. Assess the percentage of TILs in the stromal area: We selected
five typical views in each slide and assessed TILs score as the
total stroma area divided by the lymphocyte-occupied area.
The average value was considered the final score of the slide.
The thresholds for evaluation of the TIL levels were established as
follows: (1) 0% b low level ≤ 30%; (2) 30% b moderate level ≤ 70%;
and (3) 70% b high level ≤ 99%.
The slides were first observed under a magnification of ×200 (ocular
×10, objective ×20). Then, the typical regions were used to represent the
common situation inside the tumor and were evaluated under a
magnification of ×400 (ocular ×10, objective ×40). Each slide was
evaluated by two pathologists, and the results were considered only
when the difference between observers was less than 10%. When the
difference was more than 10% or divided into different TIL subgroups,
the two pathologists determined the final score by consensus.
Statistical Analysis
The descriptive statistics used were frequencies, percentages, and
means ± standard deviations. The outcome assessment parameters
Figure 1. Standardized approach of TIL evaluation for HNSCC patients.
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DFS was defined as the time from the first day after treatment to
disease progression or death from any cause. DSS was calculated from
the time of the first operation to the time of death or last follow-up;
patients who died from causes other than HNSCC were censored at
the time of death. The Kaplan–Meier method was used to provide
estimates of the DFS and DSS rates. Statistical significance was
determined with the log-rank test. A Cox proportional hazards model
(forward method) was used to adjust for the effects of other potential
confounders. All of the tests were two-sided, and P values less than
0.05 were considered statistically significant. All of the statistical
analyses were performed using SPSS software, version 17.0 for
Windows (SPSS, Chicago, IL, USA).Results
Patient Demographics
Between January 1998 and January 2011, a total of 202 successive
patients with primary HNSCC were scheduled for radical surgery in
our hospital. There were 134 (66.3%) males and 68 (33.7%) females.
The mean age of the patients was 60.7 ± 13.5. The primary sites were
the oral cavity in 191 patients (94.6%) and the oropharynx in 11
patients (5.4%). There was no statistically significant correlation
between the natural history of tumors in HNSCC patients and the
TIL level.
Of the patients, 93 (46.0%) were smokers, 104 (51.5%) were
non-smokers, and five (2.5%) had missing information. Smoking
able 1. Baseline Demographics of the 202 Patients in this Study
ariable No. (%) Low TILs Moderate TILs High TILs P
No. (%) No. (%) No. (%)
ge, yrs.: mean ± SD 60.74 ± 13.48 0.906
≤60 97 (48.0%) 32 (46.4%) 36 (48.0%) 29 (50.0%)
N60 105 (52.0%) 37 (53.6%) 39 (52.0%) 29 (50.0%)
ex 0.097
Male 134 (66.3%) 51 (73.9%) 43 (57.3%) 40 (69.0%)
Female 68 (33.7%) 18 (26.1%) 32 (42.7%) 18 (31.0%)
T stage 0.008
T1 32 (15.8%) 8 (11.6%) 12 (16.0%) 12 (20.7%)
T2 53 (26.2%) 12 (17.4%) 23 (30.7%) 18 (31.0%)
T3 38 (18.8%) 9 (13.0%) 15 (20.0%) 14 (24.1%)
T4 79 (39.2%) 40 (58.0%) 25 (33.3%) 14 (24.1%)
N stage 0.130
N0 120 (59.4%) 36 (52.2%) 44 (58.7%) 40 (69.0%)
N1 30 (14.9%) 9 (13.0%) 15 (20.0%) 6 (10.3%)
N2 52 (25.7%) 24 (34.8%) 16 (21.3%) 12 (20.7%)
N3 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
ite 0.112
Oral cavity 191 (94.6%) 62 (89.9%) 72 (96.0%) 57 (98.3%)
Oropharynx 11 (5.4%) 7 (10.1%) 3 (4.0%) 1 (1.7%)
moking history 0.042
Smoker 93 (46.0%) 39 (56.5%) 25 (33.3%) 29 (50.0%)
Nonsmoker 104 (51.5%) 28 (40.6%) 48 (64.0%) 28 (48.3%)
Missing 5 (2.5%) 2 (2.9%) 2 (2.7%) 1 (1.7%)
lcohol history 0.048
Drinker 58 (28.7%) 26 (37.7%) 13 (17.3%) 19 (32.8%)
Nondrinker 139 (68.8%) 41 (59.4%) 60 (80.0%) 38 (65.5%)
Missing 5 (2.5%) 2 (2.9%) 2 (2.7%) 1 (1.7%)
erineural invasion 0.150
Absence 146 (72.3%) 47 (68.1%) 50 (66.7%) 49 (84.5%)
Presence 23 (11.4%) 10 (14.5%) 9 (12.0%) 4 (6.9%)
Missing 33 (16.3%) 12 (17.4%) 16 (21.3%) 5 (8.6%)
ascular emboli 0.286
Absence 164 (81.2%) 55 (79.7%) 58 (77.3%) 51 (87.9%)
Presence 5 (2.5%) 2 (2.9%) 1 (1.3%) 2 (3.4%)
Missing 33 (16.3%) 12 (17.4%) 16 (21.3%) 5 (8.6%)
iffuse infiltration 0.261
Absence 137 (67.8%) 48 (69.6%) 45 (60.0%) 44 (75.9%)
Presence 32 (15.8%) 9 (13.0%) 14 (18.7%) 9 (15.5%)
Missing 33 (16.3%) 12 (17.4%) 16 (21.3%) 5 (8.6%)
icroscopic ECS 0.012
Absence 160 (79.2%) 50 (72.5%) 57 (76.0%) 53 (91.4%)
Presence 9 (4.5%) 7 (10.1%) 2 (2.7%) 0 (0.0%)
Missing 33 (16.3%) 12 (17.4%) 16 (21.3%) 5 (8.6%)
djuvant radiotherapy 0.012
Yes 142 (70.3%) 56 (81.2%) 53 (70.7%) 55 (68.8%)
No 60 (29.7%) 13 (18.8%) 22 (29.3%) 25 (31.2%)
16 status* 0.406
p16+ 2 (18.2%) 1 (14.3%) 1 (33.3%) 0 (0.0%)
p16− 8 (72.7%) 6 (85.7%) 1 (33.3%) 1 (100.0%)
Missing 1 (9.1%) 0 (0.0%) 1 (33.3%) (0.0%)
ote: * p16 status was evaluated only in patients with oropharyngeal squamous cell carcinoma.
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history of smoking had a lower TIL level. There were 58 drinkers
(28.7%) and 139 non-drinkers (68.8%), and non-drinkers showed a
higher TIL level (P = .048). The numbers of patients at each clinical
stage were as follows: T1 (n = 32, 15.8%), T2 (n = 53, 26.2%), T3 (n
= 38, 18.8%), and T4 (n = 79, 39.2%). The clinical stage was
associated with the TIL level (P = .008). One hundred forty-two
(70.3%) of 202 patients underwent radiotherapy after surgery, and 60
patients (29.7%) did not undergo radiotherapy. The history of
radiation was associated with the TIL level (P = .012). An analysis of
p16 expression in all 11 patients with oropharyngeal squamous cell
carcinoma revealed that two cases were positive, eight cases were
negative, and one case was missing. The p16 status was not associated
with the TIL level (P = .406).
The pathological nodal status of the patients was as follows: pN0 (n
= 120, 59.4%), pN1 (n = 30, 14.9%), and pN2 (n = 52, 25.7%). No
statistical correlation was found between the pathological nodal status
and the TIL level (P = .130). A total of 169 successive cases were
available for the analysis of histologic signs of severity (perineural
invasion, vascular emboli, diffuse infiltration) and extracapsular
spread (ECS) status. Specifically, perineural invasion was present in
23 cases (11.4%) and absent in 146 cases (72.3%); vascular emboli
were present in five cases (2.5%) and absent in 164 cases (81.2%);
and diffuse infiltration was present in 32 cases (15.8%) and absent in
137 cases (67.8%). There were no significant differences between the
TIL level and perineural invasion (P = .150), vascular emboli (P =
.286) and diffuse infiltration (P = .261). Notably, the ECS status was
related to the TIL level (P = .012). There were nine ECS-positive
cases (4.5%) and 160 ECS-negative cases (79.2%), and the patients
who presented with ECS had a significantly lower level of TILs than
those without ECS. Detailed data are available in Table 1.
Patients With High TIL Level Showed a Better Prognosis
The cut-off date for follow-up was December 1, 2013. Among the
202 patients, 27 (13.4%) were excluded because of loss to follow-up,
and 175 patients provided follow-up data. The median follow-up
time was 52 months (range, 5-153 months) for the survivors. No
patients died during the perioperative period. During the follow-up
period, 103 patients (58.9%) died. Eight of these patients died of
causes other than cancer, including cardiovascular disease in two
cases, lung infection in three patients and uncertain causes in two
patients. A total of 109 patients (62.3%) developed recurrence.
In addition, 16 patients developed a second primary carcinoma.
The DFS rate was 37.7% (66/175), and the DSS rate was 45.7%
(80/175).
By Kaplan-Meier analysis, patients with a high TIL level showed a
lower recurrence rate than those with a moderate TIL level (48.1%
versus 66.7%, P = .024, Figure 2) or low TIL level (48.1% versus
70.7%, P = .006, Figure 2), but there was no difference between the
low and moderate levels (70.7% versus 66.7%, P = .596, Figure 2).
Similarly, improved DSS was noted for HNSCC patients with a high
TIL level compared with moderate TIL level (40.7% versus 60.3%,
P = .027, Figure 3) or low TIL level (40.7% versus 60.3%, P = .024,
Figure 3). There was no significant difference in DSS between
patients with low and moderate TIL levels (60.3% versus 60.3%, P =
.915, Figure 3). The type of tumor stroma area was not related to
patient prognosis, and there was no significant difference regarding
recurrence between the cell-rich type and moderate type (58.5%
versus 69.2%, P = .126), cell-rich type and stroma-rich type (58.5%T
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Nversus 64.2%, P = .577) or moderate type and stroma-rich type
(69.2% versus 64.2%, P = .252, Figure 4). The survival rate was also
not significantly different between patients with the cell-rich type and
moderate type (48.8% versus 65.4%, P = .074), cell-rich type and
stroma-rich type (48.8% versus 56.7%, P = .478) or moderate type
and stroma-rich type (65.4% versus 56.7%, P = .180, Figure 5).
TIL Level is an Independent Risk Factor for DFS and DSS
Using Cox proportional hazards regression models, we first
estimated independent predictive factors for DFS. The univariate
analyses in the entire group showed that the TIL level (hazard ratio
(HR): 0.730, 95% CI: 0.578-0.924, P = .009), pN status (HR:
1.418, 95% CI: 1.149-1.750, P = .001), and site (HR: 2.642, 95%
CI: 1.324-5.273, P = .006) were related to DFS. Multivariate analysis
Figure 2. Kaplan–Meier survival curve for TIL level and DFS time
according to different TIL levels. Figure 4. Kaplan–Meier survival curve for types of tumor stroma
and DFS time according to different types of tumor stroma.
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P = .049) and pN status (HR: 1.351, 95% CI: 1.091-1.673, P =
.006) were independent risk factors for DFS.
The univariate analyses of all patients evaluated for DSS revealed
that the TIL level (HR: 0.758, 95% CI: 0.590-0.974, P = .031),
T stage (HR: 1.225, 95% CI: 1.015-1.480, P = .035), pN status
(HR: 1.692, 95% CI: 1.351-2.118, P b .001), site (HR: 3.173, 95%
CI: 1.583-6.359, P = .001), and sex (HR: 0.615, 95% CI:
0.386-0.980, P = .041) were correlated with DSS. The multivariate
analysis confirmed that pN status (HR: 1.600, 95% CI: 1.250-2.049,
P b .001) and site (HR: 2.253, 95% CI: 1.093-4.642, P = .028) were
independent predictive factors for DSS (Table 2).Figure 3. Kaplan–Meier survival curve for TIL level and DSS time
according to different TIL levels.Discussion
As indicated previously, many studies are incomparable because of the
inconsistency in assessment approach and threshold, making the role
of TILs in HNSCC uncertain [13]. Based on approaches for
evaluating TIL levels in other fields, we developed a method aimed at
evaluating TIL levels in HNSCC, and the results proved feasible.
Many authors have suggested that the TIL level carries more
predictive value than TNM stage, and others believe that the TIL
level can provide detailed stratification on the basis of TNM stage. T
stage is the foundation of the TNM stage, and it has been proven toFigure 5. Kaplan–Meier survival curve for types of tumor stroma
and DSS time according to different types of tumor stroma.
Table 2. Univariate Analysis and Multivariate Analysis for the Estimation of Risk Factors for the
DFS and DSS in Patients with HNSCC
Variable Hazard
Ratio
95% Confidence
Interval
P
Univariate analysis for DFS
TIL level (high, moderate, low) 0.730 0.578-0.924 0.009
Type of tumor stromal area (cell-rich, middle, stroma-rich) 1.062 0.869-1.299 0.555
T stage (T1, T2, T3, T4) 1.055 0.888-1.255 0.542
pN status (N0, N1, N2, N3) 1.418 1.149-1.750 0.001
Site (Oral versus Oropharynx) 2.642 1.324-5.273 0.006
Age (≤60 versus N60) 1.030 0.706-1.504 0.877
Sex (male versus female) 0.873 0.577-1.320 0.519
Tobacco use (absence versus presence) 1.057 0.750-1.489 0.753
Alcohol use (absence versus presence) 1.050 0.725-1.520 0.796
Radiotherapy (Yes versus No) 1.072 0.720-1.597 0.731
Multivariate analysis for DFS
TIL level (high, moderate, low) 0.786 0.618-0.999 0.049
pN status (N0, N1, N2, N3) 1.351 1.091-1.673 0.006
Site (oral versus oropharynx) 1.935 0.947-3.952 0.070
Univariate analysis for DSS
TIL level (High, moderate, low) 0.758 0.590-0.974 0.031
Type of tumor stromal area (cell-rich, middle, stroma-rich) 1.089 0.878-1.350 0.439
T stage (T1, T2, T3, T4) 1.225 1.015-1.480 0.035
pN status (N0, N1, N2, N3) 1.692 1.351-2.118 b0.001
Site (oral versus oropharynx) 3.173 1.583-6.359 0.001
Age (≤60 versus N60) 0.919 0.613-1.380 0.685
Sex (male versus female) 0.615 0.386-0.980 0.041
Tobacco use (absence versus presence) 1.220 0.836-1.780 0.303
Alcohol use (absence versus presence) 1.438 0.964-2.147 0.075
Radiotherapy (Yes versus No) 1.073 0.701-1.643 0.744
Multivariate analysis for DSS (forward method)
Site (oral versus oropharynx) 2.253 1.093-4.642 0.028
pN status (N0, N1, N2, N3) 1.600 1.250-2.049 b0.001
TILs level (high, moderate, low) 0.843 0.647-1.098 0.206
T stage (T1, T2, T3, T4) 0.991 0.800-1.228 0.934
Sex (male versus female) 0.703 0.438-1.129 0.145
*Note: DFS, disease-free survival; DSS, disease-specific survival; TILs: Tumor infiltrating
lymphocyte.
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associated with T stage; specifically, more advanced tumors showed
fewer infiltrating lymphocytes. Moreover, patients with a lower TIL
level were found to require radiation treatment after surgery. These
results indicated that patients with higher TIL levels may have a better
prognosis.
By Kaplan–Meier analysis, we confirmed a significant difference in
prognosis between the high TIL level group and the other two groups.
Patients with high TIL levels showed a better outcome in both DFS
and DSS. Using the Cox regression model, TIL level was identified as
an independent predictor of DFS and was closely related to DSS.
Therefore, the TIL level has great predictive value for HNSCC
patients, and these results are in accordance with those of previous
studies and our hypothesis.
A few previous studies have focused on the relationship between
health behaviors and TILs, specifically smoking and drinking history
[14]. In this study, smokers and drinkers tended to have lower TIL
levels, which is consistent with the results of Wolf et al. [14].
Unhealthy behaviors may damage the liver, thereby weakening the
immune response.
As an immune biomarker, the TIL level reflects the ability of the
immune system to protect against malignant cells. The immune
system targets cancer by lysing tumor cells and secreting cytokines
[15,16]. We predict that only when there are sufficient numbers of
lymphocytes or antitumor factors can the immune microenvironment
eliminate tumor tissue, which is why only high TIL levels wereassociated with better prognosis. Interestingly, ECS was also found to
be related to the TIL levels, as patients with ECS showed lower TIL
levels. Notably, no patients in the subgroup of high TIL levels
developed ECS. The lack of TILs in the primary site reflected the
immune deficiency. Therefore, we speculated a lack of TILs in the
primary site could reflect the immune status of the corresponding
metastatic lymph nodes. For these patients, we hypothesized that the
immunity of metastatic nodes was not sufficient to eliminate the
tumor and that this deficiency allowed the carcinoma cells to be able
to break through the lymph node capsule. To test this hypothesis, a
further study of the association between the TIL level of the primary
site and the ECS of metastatic lymph nodes might be required and
will be performed in the future.
From the microscopic perspective, the development of tumor
tissues leads to hypoxia, which decreases the pH and significantly
changes the tissue microenvironment. Previous studies have shown
that the expression of signaling molecules such as VEGF, GPD1L and
HIF-1 changes during cancer progression, and some researchers now
believe that these factors act on lymphocytes and alter the proportion
of T cell subsets. For instance, Yu et al. [17] reported that
lymphocytes in the tumor microenvironment can affect the balance
between the immune response and tolerance, leading to different
outcomes. With tumor development, the total number of lympho-
cytes is decreased and the number of immunosuppressive cells is
increased, thereby weakening the immune environment of the tumor.
However, the TIL mechanism of action remains controversial, and
future studies are required to address TIL function [17–19].
In recent years, the localization of TILs has received increasing
attention [18,20–22]. These studies have generally categorized TILs
into two groups based on whether they are in contact with tumor
cells: stromal lymphocytes (sTILs) and intratumoral lymphocytes
(iTILs). Like much previous research, our study focused on sTILs. In
practice, we found that there were also immune cells present outside
of the tumor margins. Balermpas et al. [21] reported that the
intratumoral localization of TILs influences their prognostic impact,
and Taube et al. [20] and Tumeh et al. [22] reported that the
localization of T cells was associated with PD-L1-expressing cells.
However, because there is no official recommendation for assessing
TILs outside of tumor boundaries, we did not count these
lymphocytes using our method.
Considering our results in terms of daily clinical practice, we
recommend 70% as a threshold for clinical practice and research trials
to predict the prognosis of HNSCC patients. Although we found that
70% was the best cutoff point for the TIL level, for future TIL
assessment, we recommend that the TIL level be divided into three
groups. Currently, immunohistochemistry (IHC) is commonly used
in research on TILs (e.g., to detect CD3+, CD8+, and CD45+ cells),
but the effect of T lymphocyte subsets remains unclear [23,24]. Based
on the approach we established in this study, we will explore the
clinical value of TIL subtyping using IHC, and the three-group
approach might provide additional information. This study used
H&E staining to confirm the relationship between TILs and
prognosis, as H&E staining is convenient and easier to carry out in
clinical practice.
This study was retrospective in nature and was restricted to patient
subsets with available samples. Additionally, this study used only
H&E staining as the method of pathological analysis. Thus, all results
should be considered exploratory. This study may also be criticized
for lack of data on some important baseline factors, including the
16 Prognostic Value of TILs in Head and Neck cancer Xu et al. Translational Oncology Vol. 10, No. xx, 2016depth of invasion and tumor thickness. These limitations will be
given further consideration in future studies.
Conclusion
The assessment approach and criterion we established to evaluate
TILs in HNSCC have been proven feasible. The TIL level was clearly
related to patient prognosis, and 70% was identified as a valid
threshold for TIL assessment, with TIL levels higher than 70%
associated with a better prognosis. Thus, the TIL level may serve as an
independent predictor for DFS in HNSCC patients.
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